Engflag

Oflokem

Quick links to important sections

Oflokem

Oflokem_IT

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oflokem

Property Description
Active ingredient Ofloxacin
Form Tablet (systemic), Solution/Suspension (topical)
Pharmacological class Fluoroquinolone Antibiotic
Common use Treating bacterial infections
Origin Synthetic Compound

What is Oflokem and Its Pharmacological Class?

Oflokem is a prescription-only medication defined by the active ingredient, Ofloxacin. This compound is classified as a synthetic antimicrobial agent belonging to the fluoroquinolone family of antibiotics, which are fundamentally quinolone derivative structures. This classification highlights the drug's potent, targeted ability to eliminate bacterial threats. Ofloxacin is a second-generation fluoroquinolone with a broad spectrum of activity against many susceptible bacteria.

Composition and Available Forms (Tablet vs. Topical)

The medication is a single-ingredient product (monotherapy) where Ofloxacin is the sole active component. The drug is presented in distinct dosage form(s) based on the required route of administration. For systemic use (to act throughout the body), Oflokem is supplied as a standard tablet. Conversely, for localized topical use, the compound is prepared as Ofloxacin Topical, available as an ophthalmic solution or ear drops/suspension suspended in an aqueous solution base. Ofloxacin is an established medicine used for combating a range of bacterial diseases globally. This dual formulation—systemic versus topical—allows for the precise delivery of the synthetic antimicrobial agent to the specific site of infection.

What Is Oflokem's General Therapeutic Purpose?

The primary general purpose of Oflokem is to effectively combat infections caused by susceptible bacteria. The drug achieves this through its inherent bactericidal action—meaning it actively kills the bacteria rather than merely inhibiting their growth. This essential function is clinically recognized for its efficiency in stopping bacterial cell division and facilitating microbial pathogen eradication. By actively working toward this goal, Oflokem helps resolve the infection and supports the body's natural recovery process.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Oflokem?

Possible side effects and safety information

The systemic use of Oflokem (Ofloxacin), a fluoroquinolone antibiotic, is associated with an official profile of adverse drug reactions, some classified as serious and potentially irreversible, affecting multiple body systems. The documented safety concerns are grouped by frequency and the organ system involved, reflecting information from regulatory documents.

Officially Classified Adverse Reactions

Adverse effects are categorized based on official frequency classifications:

  • Common (1% to 10%): Nausea, diarrhea, dizziness, headache, insomnia, vomiting, and skin reactions such as rash and pruritus.
  • Rare (0.01% to 0.1%): Tendinitis, joint pain (arthralgia), and muscle pain (myalgia).
  • Very Rare (Less than 0.01%): Tendon rupture and acute renal failure.

Serious Adverse Reactions and Safety Constraints

The regulatory label highlights several serious risks across various System Organ Classes:

  • Musculoskeletal and Nervous Systems: Potential for tendon rupture (which can occur within 48 hours or months after stopping treatment) and peripheral neuropathy (nerve damage, sometimes irreversible).
  • Cardiac and Vascular: Risks include QT interval prolongation and the potential for aortic aneurysm or dissection (bulges or tears in the main artery).
  • Psychiatric and CNS: The label documents the potential for serious effects such as seizures, suicidal thoughts, and other mood disturbances, sometimes occurring soon after the first dose.
  • Population Risk: The risk of tendon rupture and aortic injury is specifically noted to be elevated in older adults (over 60) and organ transplant recipients. Systemic use is not approved for patients under 18 years old.

The official documentation defines the drug's safety profile, noting that risks are elevated with concurrent use of corticosteroids and in patients with a history of epilepsy or a lowered seizure threshold.

Overdose and Emergency Response

The official regulatory documentation mandates that any suspected overdose with Oflokem requires seeking immediate medical attention and contacting emergency services immediately. This urgent action is required due to the potential for severe, life-threatening outcomes officially documented in prescribing information.

Documented Manifestations

An overdose may present with a range of central nervous system (CNS) manifestations, including dizziness, confusion, disorientation, lethargy, and tremor. Epileptic seizures and progression to status epilepticus or coma are officially documented severe events. Gastrointestinal symptoms like nausea may also occur. A critical concern is the documented risk for prolongation of the QT interval, which necessitates ECG monitoring in a hospital setting due to the risk of serious cardiac arrhythmias.

Official Procedures and Constraints

Management is strictly symptomatic and supportive treatment, as regulatory bodies confirm that no specific antidote is known. Officially described procedures may include immediate gastric lavage and forced diuresis to aid elimination. Hospital monitoring for an observation period is mandated. Regulatory documentation specifically notes that increased severity of overdose is possible in patients with renal impairment, a population constraint that factors into the required medical observation.

Therapeutic Uses of Oflokem

What Oflokem Treats: Main Uses and Benefits

Oflokem (containing the active ingredient ofloxacin) is used for managing certain bacterial infections and is generally applied in contexts where additional symptomatic support is needed. The core therapeutic domains addressed involve infections of the lungs, skin, bladder, and reproductive organs.

Therapeutic Scope and Patient Benefit

This medicine is commonly used across conditions where symptoms arise from acute bacterial infections within the respiratory tract, urinary and reproductive tracts, and localized areas like the skin, eyes, and ears. It helps address symptom clusters such as fever, persistent cough, and painful urination. It is applied in clinical settings that involve acute or unstable symptom patterns, helping patients cope more steadily with difficult episodes. This provides support that helps ease the overall symptom burden and may assist with maintaining functional stability when symptoms interfere with routine activities.

“Oflokem is relevant when supportive symptom management is appropriate, particularly in infections presenting with disruptive manifestations.”

Quick Fact: Relief for Acute Discomfort
Oflokem is relevant for easing symptoms that create noticeable physiological strain, such as the pain and urgency associated with certain bladder infections, and contributes to improved day-to-day comfort during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus overview of Ofloxacin

Eligibility and Restrictions for Use

Who can and cannot use Oflokem?

Oflokem, containing the antibiotic Ofloxacin, is an official regulatory document-defined prescription medication with strict eligibility criteria governing who may use it. These criteria are based on age, pre-existing conditions, and physiological status.

Contraindicated Populations (Must Not Use)

Official labeling mandates that Oflokem is contraindicated and must not be used by the following groups:

  • Hypersensitivity: Individuals with a known allergy or hypersensitivity to ofloxacin, to any other quinolone or fluoroquinolone antibiotic, or to any component of the formulation.
  • Pediatric/Adolescent Use: Children and growing adolescents (generally under 18 years old) for systemic use, due to the potential for damage to developing cartilage.
  • Pregnancy and Lactation: Women who are pregnant or are breastfeeding.
  • Pre-existing Conditions: Patients with a history of epilepsy or other central nervous system disorders that lower the seizure threshold, or a history of tendon disorders related to previous fluoroquinolone administration.

Restricted or Cautionary Use

Use requires special consideration and potential dose adjustment for patients with impaired kidney function (renal impairment) or impaired liver function (hepatic impairment). Caution is also advised in the elderly, who may have an increased risk of tendinitis and tendon rupture.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Oflokem (Ofloxacin) documents several specific interaction patterns that may alter drug exposure or physiological effects.

Pharmacokinetic and Absorption Interactions

Co-administration of Oflokem with metal cation-containing products, such as antacids (containing magnesium or aluminum), sucralfate, or mineral supplements containing iron or zinc, results in reduced absorption of Oflokem due to chelation. To mitigate this effect and maintain systemic exposure, Oflokem must be administered at least two hours before or two hours after these preparations. Additionally, substances that compete for active transport at the renal tubular excretion site, such as Probenecid, officially lead to decreased Oflokem clearance and increased systemic exposure.

Pharmacodynamic and Additive Risks

Certain combinations carry officially documented additive risks. Co-administration with Theophylline or certain Non-Steroidal Anti-inflammatory Drugs (NSAIDs), such as Fenbufen, may cause a pronounced lowering of the cerebral seizure threshold. The risk of tendon rupture is heightened when Oflokem is taken concurrently with systemic corticosteroids, a risk officially noted as increased in the elderly population. Furthermore, official documentation states that Oflokem may increase the effect of coumarin derivatives, such as Warfarin, necessitating careful monitoring due to the risk of bleeding.

Mechanism of Action

How Oflokem Works: Mechanism of Action

Targeting Bacterial DNA Gyrase and Topoisomerase IV

Ofloxacin’s action is determined by its direct inhibitory activity on two critical prokaryotic enzymes: Bacterial DNA Gyrase (Topoisomerase II) and Topoisomerase IV. These enzymes are essential for managing the physical structure of the bacterial DNA (supercoiling and segregation), making them the molecular targets for the compound.

Inducing Irreparable Genetic Damage (Bactericidal Cascade)

By binding to the enzyme-DNA complex, Ofloxacin prevents the necessary re-ligation of cleaved DNA strands, thus creating and stabilizing catastrophic double-strand DNA breaks in the bacterial chromosome. This genetic damage halts DNA replication and triggers the bacterial cell's intrinsic stress response, which leads to rapid, active bactericidal (cell-killing) activity.

Constraint by Bacterial Efflux Mechanisms

The compound's functional capacity depends on achieving a sufficient intracellular concentration to inhibit the target enzymes. Specific bacterial efflux pumps, however, can actively transport the Ofloxacin molecule out of the cell. This transport-based limitation functionally weakens the inhibitory mechanism, constraining the effect against resistant bacterial mechanisms.

Dosage and Administration Information

Oflokem, which contains the active ingredient ofloxacin, is administered through several official routes depending on the site of intended action: systemically via oral tablets or intravenous (IV) infusion, or topically as ophthalmic or otic solutions. The standard systemic adult dosing typically ranges from 200 mg to 400 mg, most commonly prescribed for administration twice daily (every 12 hours). While the total daily dose usually does not exceed 800 mg, doses up to 400 mg may be given as a single daily dose, preferably in the morning. Treatment duration is regulated by the specific condition, ranging from short courses of 3 to 7 days up to 6 weeks for deep-seated infections.

For oral use, tablets should be swallowed whole with sufficient liquid and may be taken with or without food. Maintenance of adequate hydration is required throughout systemic therapy. If the IV route is utilized, the solution must be administered slowly over approximately 60 minutes.

Dosage adjustments are essential for certain patient groups. Individuals with impaired renal function or severe hepatic impairment require a modified dose or frequency pattern to prevent drug accumulation. In contrast, older adults do not require a dose adjustment based on age alone, unless their concurrent kidney function is reduced. For topical use, specific preparation steps apply: the otic solution must be warmed by holding the bottle in the hand before placing the drops into the ear canal.

Recent Clinical Evidence

Oflokem: Recent Clinical Evidence

The research base for Oflokem (ofloxacin) is primarily comprised of short-term, randomized controlled trials (RCTs) and comparative clinical trials, which were used to explore its activity against susceptible bacteria across several types of infection. Findings from these studies are continuously monitored by regulatory bodies like the FDA and EMA and contribute to the broader evidence landscape, focusing on short-term microbiological and clinical outcomes.

Research on Systemic Uses: Urinary and Respiratory Tract Infections

Oflokem was studied for conditions characterized by fluctuating or episodic manifestations of urinary tract infections, covering both uncomplicated and more complicated cases. Short-term RCTs research examined outcomes related to microbiological eradication—meaning the target bacteria were cleared from the urine—and clinical success defined by the resolution of symptoms. Findings describe patterns observed in the studies where trials reported measurements of these short-term microbiological and symptom-based endpoints.

Similarly, Oflokem was evaluated in patients experiencing acute flare-ups of chronic bronchitis, which are conditions involving periods of heightened symptoms. The research described findings related to measurements of clinical response that were reported in the studied groups. Current governmental and intergovernmental bodies emphasize that, due to potential serious risks associated with the fluoroquinolone class, the evidence suggests reserving the systemic use of this medication for these infections only when no alternative treatment options are available.

Research on Topical Uses: Eye and Ear Infections

For localized infections, Oflokem was studied for bacterial conjunctivitis and corneal ulcers using ophthalmic solutions. Trials monitored microbiological eradication rates that were distinct from the rates reported for the placebo group. The evidence level for these specific topical uses is characterized as high for achieving the designated endpoints within the study durations.

Research on the ear drop formulation was studied for conditions associated with acute or disruptive episodes, specifically chronic ear infections with drainage (otorrhea). The studies report how symptoms evolved in the observed populations, examining outcomes related to systemic or functional imbalance over a typical course of treatment. The evidence level for these topical otic applications is broadly considered high due to the consistency of results across multiple trials.

Research in Specific Patient Groups and Remaining Uncertainty

Research has explored Oflokem's use in older adults (typically over 65 years of age). Studies in this group data show patterns related to absorption that are similar to patterns observed in younger adults. However, older patients may have decreased renal function; evidence suggests that elimination of the drug may be slower, which was observed to be associated with higher concentrations reported in the body. For pediatric populations, systemic use is restricted, but the topical formulation was studied for ear and eye infections.

The primary research across most indications focused on short-term microbiological and clinical endpoints. Long-term effects are not fully established, and there is limited information for long-term outcomes regarding sustained response. The ongoing regulatory emphasis on reserved use for systemic indications reflects the scientific understanding that, despite reported short-term measurements, the overall risk-benefit balance is continuously monitored.

Key Studies & References

  1. Ophthalmic Antibiotics Therapeutic Class Review (Review including Ofloxacin ophthalmic use)
  2. Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines (Review of FQ use in UTI)

Frequently Asked Questions (FAQ)

Common questions about Oflokem (FAQ)

Q: What is Oflokem prescribed for besides common infections?

A: Oflokem (Ofloxacin) is indicated for several specific bacterial infections, according to official product information. These uses include treating certain instances of acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, uncomplicated skin and skin structure infections, and chronic bacterial prostatitis. It is also used for complicated and uncomplicated urinary tract infections.

Q: What should I do if I miss a dose of Oflokem?

A: Official guidance on managing missed doses states that a person may take the dose as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed one is generally skipped. It is specified that double or extra doses should not be taken to compensate for a dose that was missed.

Q: Does Oflokem cause sensitivity to the sun?

A: Yes, regulatory documents indicate that Oflokem (Ofloxacin) can cause photosensitivity, which is an increased reaction to sunlight. Official information suggests avoiding unnecessary exposure to strong sunlight or artificial UV light sources (such as sunlamps) while undergoing treatment and for a period after therapy is complete.

Q: What happens if I drink alcohol while taking Oflokem?

A: Official patient advice suggests limiting or avoiding alcohol intake while taking Oflokem. This is because combining Oflokem with alcohol may increase the risk of certain side effects, such as dizziness or lightheadedness.

Q: Are there certain foods or drinks to avoid when using Oflokem?

A: Regulatory documents advise separating Oflokem from products that contain metal cations (positively charged minerals), such as certain antacids, mineral supplements, and usually dairy products. These ingredients can interfere with the absorption of Oflokem, and regulatory documents note that these products must be separated from Oflokem by an appropriate time interval, usually noted in the specific patient instructions.

Q: Can Oflokem be used for a viral infection like the flu?

A: No, Oflokem is classified as a fluoroquinolone antibiotic that is specifically designed to work by killing susceptible bacteria. According to its pharmacological classification, it is not effective against viral infections, such as the flu or the common cold.

Q: Can Oflokem affect your blood sugar levels?

A: Yes, official warnings mention that the use of Oflokem (Ofloxacin) has been associated with changes in blood glucose levels. This includes reports of both hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar). This information is particularly relevant for individuals who are currently managing diabetes.

Q: What is the common purpose of Oflokem in ear or eye drops?

A: The purpose of the topical (ear or eye drop) formulation of Oflokem is to provide localized treatment for specific bacterial infections. This includes treating bacterial infections of the eyes, such as conjunctivitis and corneal ulcers, and certain bacterial infections affecting the ears, like acute otitis externa.

Q: Is Oflokem a strong or reserved antibiotic?

A: Regulatory guidance now advises that systemic Oflokem (Ofloxacin) should generally be reserved for use only in patients who have no alternative treatment options available for certain infections. This policy is in place due to the potential risk of serious adverse reactions associated with the fluoroquinolone class.

Q: Does Oflokem have any interactions with dietary supplements?

A: Yes, official warnings include interactions with mineral-containing supplements (such as iron, zinc, or calcium), which must be taken separately by several hours to avoid reduced absorption of Oflokem. Additionally, some regulatory warnings advise caution regarding supplements that may affect the heart’s electrical activity (QT interval).

Q: How does Oflokem relate to the development of resistant bacteria?

A: Like all antibiotics, the use of Oflokem contributes to the potential for bacteria to develop resistance. Regulatory bodies caution that it is essential to use the medication exactly as directed to help ensure complete clearance of the infection and to reduce the potential for resistant organisms to emerge.

Q: What happens if I stop taking Oflokem before the full course is finished?

A: Official patient information strongly advises that the entire course of medication be taken as prescribed, even if symptoms begin to improve quickly. Stopping early may prevent the complete elimination of the infection-causing bacteria, which is associated with the potential for the infection to return or for resistant bacteria to emerge.

Q: Is there a maximum time Oflokem can be taken for?

A: The maximum duration of treatment with Oflokem is determined by the specific infection being addressed and its severity. While short courses can be a few days, treatment for certain deep-seated infections, such as bacterial prostatitis, may be prescribed for durations up to six weeks.

Q: Can Oflokem be crushed or split?

A: Official patient information states that tablets should be swallowed whole with an appropriate amount of liquid. Unless there is explicit professional guidance to do so, crushing or splitting tablets is generally not advised to ensure the medication works as intended.

Q: Can taking Oflokem make birth control less effective?

A: Authoritative public health guidelines classify quinolones (including Oflokem/Ofloxacin) as not typically restricting the use of combined hormonal contraceptives. This information is a general regulatory statement; however, the efficacy of any contraceptive method can never be guaranteed.

Q: Is Oflokem used to treat sexually transmitted infections (STIs)?

A: Oflokem has regulatory indications for treating certain sexually transmitted infections, such as non-gonococcal cervicitis/urethritis. However, due to increasing rates of bacterial resistance in many regions, its use for infections like gonorrhea is often no longer recommended by some health authorities.

Q: How quickly does Oflokem start working?

A: While the time required for symptom relief can vary, official regulatory documents note that the drug may affect the body's systems shortly after the first dose. For instance, some serious effects, such as tendon damage, have been reported to occur within 48 hours of starting treatment.

Q: Can Oflokem change the results of certain lab tests?

A: Official information and related research suggest that Oflokem may sometimes interfere with the results of certain lab screening tests. This interference has been documented with tests used to identify substances like urinary porphyrins, which can potentially lead to an inaccurate (false-positive) result.

Q: Can Oflokem cause headaches or blurred vision?

A: Yes, headaches are classified as a common side effect of systemic Oflokem according to regulatory labels. Blurred vision has also been reported as a side effect, particularly in patients using the topical ophthalmic solution, and requires professional consultation if it occurs.

Q: What should I look out for if I have a history of seizures and take Oflokem?

A: Official warnings state that Oflokem can affect the central nervous system (CNS). Patients with a history of epilepsy or seizure disorders should be aware that the drug is described as potentially lowering the seizure threshold.

Q: Can Oflokem affect your mood or cause anxiety?

A: Yes, official regulatory documents note that Oflokem belongs to a class of antibiotics that can affect the central nervous system, leading to psychiatric reactions. Specifically documented effects include anxiety, confusion, restlessness, and other general mood disturbances.

How should Oflokem be stored and disposed of?

How to Store and Dispose of Oflokem?

Regulatory documents outline specific requirements for the storage and disposal of Oflokem (Ofloxacin).

Storage Conditions

Oflokem tablets must be stored in a closed container at room temperature, away from excessive heat, moisture, and direct light. The ophthalmic solution is typically stored between 20 C to 25 C and must be protected from freezing and light. All forms of the medication must be kept out of the reach of children.

Disposal Instructions

Unused or expired Oflokem should not be flushed down the toilet or poured down the sink. The preferred method for disposal is utilizing a drug take-back program. If a take-back option is unavailable, the medicine can be mixed with an undesirable substance (like dirt or coffee grounds) and placed in a sealed container before being thrown into the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Oflokem found in:

A-Z Index: